TomoTherapy to Introduce TQA™ at 50th Annual AAPM Meeting : Industry's First Integrated Machine QA Solution Expands Data Access, Improves Clinical Workflow for Hi·Art® Treatment System Users

Share Article

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it will introduce TQA™ at the 50th Annual American Association of Physicists in Medicine (AAPM) Meeting in Houston, July 27-31, 2008. TQA, or Tomo Quality Assurance™, is the first integrated, machine-specific quality assurance (QA) solution to be offered by a radiation therapy vendor. The TQA application streamlines the collection—and simplifies the review—of data used to monitor radiation therapy equipment and procedures. All TQA data can be easily exported for third-party validation.

News Image
TQA was built by, and for, our physics colleagues in the clinic

TQA has been developed by TomoTherapy in partnership with medical physicists experienced in the clinical use of the Hi·Art® treatment system. Bob Cravens, M.S., TomoTherapy's lead applied physicist and TQA architect, believes customer input was critical in bringing this powerful set of physics tools to market.

"TQA was built by, and for, our physics colleagues in the clinic," says Cravens. "They helped us identify key data and workflow requirements1, and provided valuable feedback throughout the development process. The result is an application that integrates easily into daily workflow, increases productivity and facilitates more informed decision-making. Additionally, it better aligns our support team with TomoTherapy customers, allowing them to share the same data set."

The TQA application leverages the Hi·Art treatment system's unique platform integration. It works by gathering data from the on-board detector and other sub-systems that monitor the device continuously during delivery. The data is then presented in a customizable, calendar-based interface that is accessible from the Hi·Art system's operator station. With this comprehensive data dashboard, any parameter's status can be identified at a glance and comparatively assessed via automated reporting and trending features.

"TQA can provide a wealth of additional information, which means I can work more proactively and better assess the system with predictive analysis," said Walter Grant, Ph.D., chief of Physics at Baylor College of Medicine and The Methodist Hospital in Houston, one of 16 customers to evaluate the application. "TQA can also save me considerable time. In evaluating the application, I have found QA measurements that took over an hour to complete, analyze and document can now be finished in 10 minutes. This will certainly make my life easier."

Cravens stated that TQA will provide immediate benefits to customers who are new to the Hi·Art platform as well: "We often hear that Hi·Art is the easiest system to use, once our customers have become familiar with it. TQA should help clinics hit the ground running even faster. It's a turnkey operation, complete with QA guidelines, that eliminates unnecessary complexity."

Noted TomoTherapy CEO Fred Robertson: "We are excited to introduce TQA at AAPM's 50th Annual Meeting. Integrated machine QA is one more example of what's possible with our truly integrated platform for radiation therapy, and one more reminder that we are really just at the beginning of our product lifecycle. There are many more productivity- and quality-focused enhancements to come."

Bob Cravens, M.S., and Walter Grant, Ph.D., will each be discussing TQA in the TomoTherapy booth during AAPM. For exact times of these and more presentations throughout the week, please visit AAPM booth #519, or the AAPM overview page on

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit

Forward-Looking Statements

Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms "will", "can" or "should" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company's control, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

1. C. Ramsey, J. Gibbons, T. Holmes, K. Jeong, K. Langen, D. Low, S. Meeks, N. Papanikolaou, K. Schubert, M. Tomsej - Mechanical and Dosimetric Quality Assurance for Helical TomoTherapy - International Journal of Radiation OncologyBiologyPhysics, Volume 69 , Issue 3 , Pages S699 - S699

©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patty Kitowski
Visit website